Detail Information of Post-Translational Modifications

General Information of Drug Transporter (DT)
DT ID	DTD0246 Transporter Info
Gene Name	SLC28A3
Transporter Name	Concentrative Na(+)-nucleoside cotransporter 3
Gene ID	64078
UniProt ID	Q9HAS3

Post-Translational Modification of This DT
Overview of SLC28A3 Modification Sites with Functional and Structural Information
Sequence	M E L R S T A A P R A E G Y S N V G F Q N E E N F L E N E N T S G N N S I R S R A V Q S R E H T N T K Q D E E Q V T V E Q D S P R N R E H M E D D D E E M Q Q K G C L E R R Y D T V C G F C R K H K T T L R H I I W G I L L A G Y L V M V I S A C V L N F H R A L P L F V I T V A A I F F V V W D H L M A K Y E H R I D E M L S P G R R L L N S H W F W L K W V I W S S L V L A V I F W L A F D T A K L G Q Q Q L V S F G G L I M Y I V L L F L F S K Y P T R V Y W R P V L W G I G L Q F L L G L L I L R T D P G F I A F D W L G R Q V Q T F L E Y T D A G A S F V F G E K Y K D H F F A F K V L P I V V F F S T V M S M L Y Y L G L M Q W I I R K V G W I M L V T T G S S P I E S V V A S G N I F V G Q T E S P L L V R P Y L P Y I T K S E L H A I M T A G F S T I A G S V L G A Y I S F G V P S S H L L T A S V M S A P A S L A A A K L F W P E T E K P K I T L K N A M K M E S G D S G N L L E A A T Q G A S S S I S L V A N I A V N L I A F L A L L S F M N S A L S W F G N M F D Y P Q L S F E L I C S Y I F M P F S F M M G V E W Q D S F M V A R L I G Y K T F F N E F V A Y E H L S K W I H L R K E G G P K F V N G V Q Q Y I S I R S E I I A T Y A L C G F A N I G S L G I V I G G L T S M A P S R K R D I A S G A V R A L I A G T V A C F M T A C I A G I L S S T P V D I N C H H V L E N A F N S T F P G N T T K V I A C C Q S L L S S T V A K G P G E V I P G G N H S L Y S L K G C C T L L N P S T F N C N G I S N T F
PTM type	X-Acetylation X-Phosphorylation X: Amino Acid

Acetylation
Tyrosine	1 PTM Phenomena Related to This Residue		Click to Show/Hide the Full List
PTM Phenomenon 1	Have the potential to influence SLC28A3			[1]
Role of PTM	Potential impacts
Modified Residue	Tyrosine	Modified Location	279
Experimental Method	Co-Immunoprecipitation
Detailed Description	Acetylation at SLC28A3 Tyrosine 279 has the potential to affect its expression or activity.
Phosphorylation
Serine	9 PTM Phenomena Related to This Residue		Click to Show/Hide the Full List
PTM Phenomenon 1	Have the potential to influence SLC28A3			[2]
Role of PTM	Potential impacts
Modified Residue	Serine	Modified Location	32
Experimental Method	Co-Immunoprecipitation
Detailed Description	Phosphorylation at SLC28A3 Serine 32 has the potential to affect its expression or activity.
PTM Phenomenon 2	Have the potential to influence SLC28A3			[3] , [4]
Role of PTM	Potential impacts
Modified Residue	Serine	Modified Location	36
Experimental Method	Co-Immunoprecipitation
Detailed Description	Phosphorylation at SLC28A3 Serine 36 has the potential to affect its expression or activity.
PTM Phenomenon 3	Have the potential to influence SLC28A3			[5]
Role of PTM	Potential impacts
Modified Residue	Serine	Modified Location	44
Experimental Method	Co-Immunoprecipitation
Detailed Description	Phosphorylation at SLC28A3 Serine 44 has the potential to affect its expression or activity.
PTM Phenomenon 4	Have the potential to influence SLC28A3			[3] , [4]
Role of PTM	Potential impacts
Modified Residue	Serine	Modified Location	63
Experimental Method	Co-Immunoprecipitation
Detailed Description	Phosphorylation at SLC28A3 Serine 63 has the potential to affect its expression or activity.
PTM Phenomenon 5	Have the potential to influence SLC28A3			[6]
Role of PTM	Potential impacts
Modified Residue	Serine	Modified Location	160
Experimental Method	Co-Immunoprecipitation
Detailed Description	Phosphorylation at SLC28A3 Serine 160 has the potential to affect its expression or activity.
PTM Phenomenon 6	Have the potential to influence SLC28A3			[6]
Role of PTM	Potential impacts
Modified Residue	Serine	Modified Location	218
Experimental Method	Co-Immunoprecipitation
Detailed Description	Phosphorylation at SLC28A3 Serine 218 has the potential to affect its expression or activity.
PTM Phenomenon 7	Have the potential to influence SLC28A3			[7]
Role of PTM	Potential impacts
Modified Residue	Serine	Modified Location	381
Experimental Method	Co-Immunoprecipitation
Detailed Description	Phosphorylation at SLC28A3 Serine 381 has the potential to affect its expression or activity.
PTM Phenomenon 8	Have the potential to influence SLC28A3			[7]
Role of PTM	Potential impacts
Modified Residue	Serine	Modified Location	386
Experimental Method	Co-Immunoprecipitation
Detailed Description	Phosphorylation at SLC28A3 Serine 386 has the potential to affect its expression or activity.
PTM Phenomenon 9	Have the potential to influence SLC28A3			[6]
Role of PTM	Potential impacts
Modified Residue	Serine	Modified Location	669
Experimental Method	Co-Immunoprecipitation
Detailed Description	Phosphorylation at SLC28A3 Serine 669 has the potential to affect its expression or activity.
Threonine	2 PTM Phenomena Related to This Residue		Click to Show/Hide the Full List
PTM Phenomenon 1	Have the potential to influence SLC28A3			[2]
Role of PTM	Potential impacts
Modified Residue	Threonine	Modified Location	31
Experimental Method	Co-Immunoprecipitation
Detailed Description	Phosphorylation at SLC28A3 Threonine 31 has the potential to affect its expression or activity.
PTM Phenomenon 2	Have the potential to influence SLC28A3			[6]
Role of PTM	Potential impacts
Modified Residue	Threonine	Modified Location	417
Experimental Method	Co-Immunoprecipitation
Detailed Description	Phosphorylation at SLC28A3 Threonine 417 has the potential to affect its expression or activity.
Tyrosine	1 PTM Phenomena Related to This Residue		Click to Show/Hide the Full List
PTM Phenomenon 1	Have the potential to influence SLC28A3			[7]
Role of PTM	Potential impacts
Modified Residue	Tyrosine	Modified Location	379
Experimental Method	Co-Immunoprecipitation
Detailed Description	Phosphorylation at SLC28A3 Tyrosine 379 has the potential to affect its expression or activity.

References
1	Lys-N and trypsin cover complementary parts of the phosphoproteome in a refined SCX-based approach. Anal Chem. 2009 Jun 1;81(11):4493-501.
2	A fast sample processing strategy for large-scale profiling of human urine phosphoproteome by mass spectrometry. Talanta. 2018 Aug 1;185:166-173.
3	Proteogenomic integration reveals therapeutic targets in breast cancer xenografts. Nat Commun. 2017 Mar 28;8:14864.
4	Proteogenomics connects somatic mutations to signalling in breast cancer. Nature. 2016 Jun 2;534(7605):55-62.
5	Improve the coverage for the analysis of phosphoproteome of HeLa cells by a tandem digestion approach. J Proteome Res. 2012 May 4;11(5):2828-37.
6	Ischemia in tumors induces early and sustained phosphorylation changes in stress kinase pathways but does not affect global protein levels. Mol Cell Proteomics. 2014 Jul;13(7):1690-704.
7	Inhibition of DDR1-BCR signalling by nilotinib as a new therapeutic strategy for metastatic colorectal cancer. EMBO Mol Med. 2018 Apr;10(4):e7918.

If you find any error in data or bug in web service, please kindly report it to Dr. Yin and Dr. Li.

Detail Information of Post-Translational Modifications

Visitor Map

Correspondence